Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Intra-Cellular Therapies's ITI-1284?
ITI-1284 is a small molecule commercialized by Intra-Cellular Therapies, with a leading Phase II program in Psychosis;Generalized Anxiety Disorder (GAD)....
ITI-1284 by Intra-Cellular Therapies for Psychosis: Likelihood of Approval
ITI-1284 is under clinical development by Intra-Cellular Therapies and currently in Phase I for Psychosis. According to GlobalData, Phase I...
ITI-1284 by Intra-Cellular Therapies for Dementia: Likelihood of Approval
ITI-1284 is under clinical development by Intra-Cellular Therapies and currently in Phase I for Dementia. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of Intra-Cellular Therapies's ITI-1284?
ITI-1284 is a small molecule commercialized by Intra-Cellular Therapies, with a leading Phase I program in Psychosis. According to Globaldata,...